The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications

Tomer Adar, Shimon Shteingart, Ami Ben-Ya’acov, Ariella Bar Gill Shitrit, Dan M. Livovsky, Shimrit Shmorak, Mahmud Mahamid, Bernardo Melamud, Fiona Vernea, Eran Goldin

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Background: Involvement of eotaxin-1 in inflammatory bowel disease has been previously suggested and increased levels of eotaxin-1 have been described in both ulcerative colitis and in Crohn’s disease. The association between serum levels of eotaxin-1 and that within the colonic mucosa has not been well defined, as is the potential therapeutic value of targeting eotaxin-1. Aims: To characterize serum and intestinal wall eotaxin-1 levels in various inflammatory bowel disease patients and to explore the effect of targeting eotaxin-1 by specific antibodies in dextran sodium sulfate-induced colitis model. Methods: Eotaxin-1 levels were measured in colonic biopsies and in the sera of 60 ulcerative colitis patients, Crohn’s disease patients and healthy controls. We also followed in experimental colitis the effect of targeting eotaxin-1 by a monoclonal antibody. Results: Colon eotaxin-1 levels were significantly increased in active but not in quiescent ulcerative colitis and Crohn’s disease patients compared to healthy controls. Levels of eotaxin-1 in the colon were correlated with eosinophilia only in tissues from active Crohn’s disease patients. Our results did not show any statistically significant change in serum eotaxin-1 levels among ulcerative colitis, Crohn’s disease and healthy controls. Moreover, we demonstrate that in dextran sodium sulfate-induced colitis, targeting of eotaxin-1 with 2 injections of anti eotaxin-1 monoclonal antibody ameliorates disease activity along with decreasing colon weight and improving histologic inflammation. Conclusion: Eotaxin-1 is increasingly recognized as a major mediator of intestinal inflammation. Our preliminary human and animal results further emphasize the value of targeting eotaxin-1 in inflammatory bowel disease.

Original languageEnglish
Pages (from-to)1915-1924
Number of pages10
JournalDigestive Diseases and Sciences
Issue number7
StatePublished - 1 Jul 2016
Externally publishedYes

Bibliographical note

Funding Information:
This study was partially supported by Immune Pharmaceuticals.

Publisher Copyright:
© 2016, Springer Science+Business Media New York.


  • Eotaxin-1
  • Experimental colitis
  • Immune system
  • Inflammatory bowel disease


Dive into the research topics of 'The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications'. Together they form a unique fingerprint.

Cite this